227. オスラー病
[臨床試験数:49,薬物数:69(DrugBank:21),標的遺伝子数:23,標的パスウェイ数:132

Searched query = "Osler disease", "Hereditary hemorrhagic telangiectasia", "Osler-Weber-Rendu disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02874326
(ClinicalTrials.gov)
October 201617/8/2016Octreotide in Patients With GI Bleeding Due to Rendu-Osler-WeberAn Uncontrolled, Pilot-study Assessing the Efficacy of Octreotide Long-acting Release to Decrease Transfusion Requirements and Endoscopy Frequency in Patients With Rendu-Osler-Weber and Gastrointestinal BleedingHereditary Hemorrhagic Telangiectasia;Gastrointestinal Hemorrhage;AnemiaDrug: Octreotide LARRadboud UniversitySt. Antonius HospitalUnknown status18 YearsN/AAll15Phase 2Netherlands
2EUCTR2016-001340-19-NL
(EUCTR)
21/07/201611/07/2016The effectiveness of the drug octreotide LAR to anemia in patients with gastrointestinal bleeding due to Rendu-Osler-Weber disease.An uncontrolled, pilot-study assessing the efficacy of octreotide LAR to decrease transfusion requirements and endoscopy frequency in patients with Rendu-Osler-Weber and gastrointestinal bleeding - ROW Patients with Rendu-Osler-Weber disease (which is also called: Hereditary hemorrhagic telangiectasia);Therapeutic area: Diseases [C] - Digestive System Diseases [C06]Trade Name: Sandostatin LAR 20 mg
Product Name: Sandostatin LAR
Product Code: RVG 18236
Radboud University Medical CenterNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 2Netherlands